Some action points for the next PM
Express Pharma
MAY 7, 2024
The report goes on to advise that India’s pharma companies should invest more in developing capabilities to make generic copies of biologics (biogenerics), as more biologics are set to lose exclusivity in the period up to 2030. Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex.
Let's personalize your content